At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for ...
At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen ...
Poll: Which of the following is true about insulin products and the BPCIA?
Patient-Reported Outcomes Similar Between Adalimumab-adbm, Reference Product in VOLTAIRE-RA Study ...
At the 2024 GRx+Biosims conference, industry leaders and regulatory experts underscored the urgency of unifying global ...
At the GRx+Biosims 2024 conference, panelists explored challenges and progress in biosimilar interchangeability regulations ...
Patient-Reported Outcomes Similar Between Adalimumab-adbm, Reference Product in VOLTAIRE-RA Study ...
Sarfaraz K. Niazi, PhD, provides an overview of the current biosimilar education material offered by the FDA, emphasizing ...
Sarfaraz K. Niazi, PhD, explains the FDA's new guidelines on post-approval changes for biosimilars, emphasizing the processes for reporting modifications, comparability assessments, and the potential ...
Patient-Reported Outcomes Similar Between Adalimumab-adbm, Reference Product in VOLTAIRE-RA Study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback